Nuvation Bio Inc.
NUVB•NYSE•Healthcare•Biotechnology

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.

Company Information

SectorHealthcare
IndustryBiotechnology
CEODavid Hung
Founded2018
Employees220
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSE (NYSE)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock
Share ClassClass A Shares

Contact Information

Websitewww.nuvationbio.com
Phone332 208 6102
Address
1500 Broadway, Suite 1401 New York, New York 10036 United States

Corporate Identifiers

CIK0001811063
CUSIP67080N101
ISINUS67080N1019
EIN85-0862255
SIC2834

Leadership Team & Key Executives

Dr. David T. Hung M.D.
Founder, President, Chief Executive Officer and Chairman
Dr. Gary Hattersley Ph.D.
Chief Scientific Officer
Colleen Sjogren
Chief Commercial Officer
Philippe Pierre Sauvage
Chief Financial Officer and Principal Financial Officer
Moses Makunje CPA
Vice President of Finance and Principal Accounting and Financial Officer
Dr. Stephen Dang Ph.D.
Senior Vice President, General Counsel and Corporate Secretary
Stacy Markel
Chief People Officer
Dr. David C. Hanley Ph.D.
Chief Technical Operations Officer
Kerry A. Wentworth
Chief Regulatory Officer
Dr. David Liu M.D., Ph.D.
Chief Medical Officer